Cervical cancer occurs when abnormal cancer cells develop in the cervix due to exposure to the human papillomavirus (HPV), however not all exposures to HPV cause cervical cancer. Cervical cancer is the second most common type of cancer in women and the most greatly affects the age groups 35-39 and 60-64. It is frequently found in early stages through the use of pap test. Cervical cancer is commonly treated with chemotherapy, radiation, and surgery to remove pelvic lymph nodes with or without the removal of the ovaries and fallopian tubes. In the most severe cases, hysterectomies may be necessary. Many believe that the HPV vaccine protects against the two types of HPV that cause cervical cancer. Stage 1A in cervical cancer is defined by the fact that it can only be seen with a microscope. Stage 1A is divided into 1A1 as well as 1A2 which are separated by different sizes of growth.
Stage Ia Cervical Cancer Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Stage Ia Cervical Cancer below!
For more information on how to use Laverne, please read the How to Guide.
We have 459 products for the study of Stage Ia Cervical Cancer that can be applied to Chromatin Immunoprecipitation, Western Blot, Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry from our catalog of antibodies and ELISA kits.
Stage Ia Cervical Cancer is also known as Cervical Cancer Stage Ia, Cervical Cancer, Stage Ia, Cervical Carcinoma Stage Ia, Stage Ia Cancer Of The Cervix, Stage Ia Carcinoma Of The Cervix.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.